Hong Kong Stock Movement: Alebund-B (09637) Surges Over 10% in Early Trading as Partner R1 Presents AP306 Global Phase IIb Multi-Regional Clinical Trial Design Poster at ASN Kidney Week

Stock News10-27

According to Zhitong Finance APP, ALEBUND-B (09637) rose more than 10% in early trading. As of press time, the stock was up 8.21% at HK$17.26, with a turnover of HK$10.8661 million.

On the news front, Alebund Pharmaceuticals announced that its partner R1 has presented the study design of the global Phase IIb multi-regional clinical trial (NCT06712654) of AP306, a first-in-class oral pan-phosphate transporter inhibitor for patients with hyperphosphatemia receiving maintenance hemodialysis, in the form of a trial-in-progress poster at the ASN Kidney Week 2026.

This global Phase IIb multi-regional clinical trial is jointly sponsored by Alebund Pharmaceuticals and R1 and is currently being conducted at multiple clinical centers in the United States and China. The company announced on July 21, 2026 that the first subject had been randomized and dosed in this trial. Patient enrollment at clinical centers in the United States and China is currently ongoing. The trial is expected to be completed in the second quarter of 2027, and topline data will be disclosed in due course.

For more heavyweight Hong Kong stock news, download the Zhitong Finance app. For more Hong Kong stock and overseas wealth management information, please visit www.zhitongcaijing.com (search for "Zhitong Finance"); to join the Zhitong Hong Kong stock investment group, please add the Zhitong customer service WeChat (ztcjkf).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126857983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-27 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126857983","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Movement: Alebund-B (09637) Surges Over 10% in Early Trading as Partner R1 Presents AP306 Global Phase IIb Multi-Regional Clinical Trial Design Poster at ASN Kidney Week","media":"Stock News","content":"<p>According to Zhitong Finance APP, <b>ALEBUND-B</b> (<b>09637</b>) rose more than 10% in early trading. As of press time, the stock was up 8.21% at HK$17.26, with a turnover of HK$10.8661 million.<br><br>On the news front, Alebund Pharmaceuticals announced that its partner R1 has presented the study design of the global Phase IIb multi-regional clinical trial (NCT06712654) of AP306, a first-in-class oral pan-phosphate transporter inhibitor for patients with hyperphosphatemia receiving maintenance hemodialysis, in the form of a trial-in-progress poster at the ASN Kidney Week 2026.<br><br>This global Phase IIb multi-regional clinical trial is jointly sponsored by Alebund Pharmaceuticals and R1 and is currently being conducted at multiple clinical centers in the United States and China. The company announced on July 21, 2026 that the first subject had been randomized and dosed in this trial. Patient enrollment at clinical centers in the United States and China is currently ongoing. The trial is expected to be completed in the second quarter of 2027, and topline data will be disclosed in due course.<br><br>For more heavyweight Hong Kong stock news, download the Zhitong Finance app. For more Hong Kong stock and overseas wealth management information, please visit www.zhitongcaijing.com (search for \"Zhitong Finance\"); to join the Zhitong Hong Kong stock investment group, please add the Zhitong customer service WeChat (ztcjkf).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement: Alebund-B (09637) Surges Over 10% in Early Trading as Partner R1 Presents AP306 Global Phase IIb Multi-Regional Clinical Trial Design Poster at ASN Kidney Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement: Alebund-B (09637) Surges Over 10% in Early Trading as Partner R1 Presents AP306 Global Phase IIb Multi-Regional Clinical Trial Design Poster at ASN Kidney Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-27 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to Zhitong Finance APP, <b>ALEBUND-B</b> (<b>09637</b>) rose more than 10% in early trading. As of press time, the stock was up 8.21% at HK$17.26, with a turnover of HK$10.8661 million.<br><br>On the news front, Alebund Pharmaceuticals announced that its partner R1 has presented the study design of the global Phase IIb multi-regional clinical trial (NCT06712654) of AP306, a first-in-class oral pan-phosphate transporter inhibitor for patients with hyperphosphatemia receiving maintenance hemodialysis, in the form of a trial-in-progress poster at the ASN Kidney Week 2026.<br><br>This global Phase IIb multi-regional clinical trial is jointly sponsored by Alebund Pharmaceuticals and R1 and is currently being conducted at multiple clinical centers in the United States and China. The company announced on July 21, 2026 that the first subject had been randomized and dosed in this trial. Patient enrollment at clinical centers in the United States and China is currently ongoing. The trial is expected to be completed in the second quarter of 2027, and topline data will be disclosed in due course.<br><br>For more heavyweight Hong Kong stock news, download the Zhitong Finance app. For more Hong Kong stock and overseas wealth management information, please visit www.zhitongcaijing.com (search for \"Zhitong Finance\"); to join the Zhitong Hong Kong stock investment group, please add the Zhitong customer service WeChat (ztcjkf).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1126857983","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126857983","pubTimestamp":1793068819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to Zhitong Finance APP, ALEBUND-B (09637) rose more than 10% in early trading. As of press time, the stock was up 8.21% at HK$17.26, with a turnover of HK$10.8661 million.On the news front,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK4585":"ETF&股票定投概念","09939":"开拓药业-B","BK1574":"生物医药B类股","09637":"礼邦医药-B","MDTX":"Corgi MediaTek 2x Daily ETF","BK1191":"制药","IBBQ":"Invesco Nasdaq Biotechnology ETF","KCAI":"KraneShares China Alpha Index ETF","BMED":"iShares Health Innovation Active ETF","BK4588":"碎股","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","PSYK":"PSYK ETF","VXUS":"国际股票ETF-Vanguard","BK1515":"抗疫概念"},"translate_title":"港股走势：Alebund-B(09637)早盘大涨逾10%，合作伙伴R1于ASN肾脏周展示AP306全球IIb期多区域临床试验设计海报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"IBBJ":1,"09637":1,"IBBQ":1,"PSYK":1,"KCAI":1,"VXUS":1,"MDTX":1,"09939":1,"BMED":1},"content_text":"According to Zhitong Finance APP, ALEBUND-B (09637) rose more than 10% in early trading. As of press time, the stock was up 8.21% at HK$17.26, with a turnover of HK$10.8661 million.On the news front, Alebund Pharmaceuticals announced that its partner R1 has presented the study design of the global Phase IIb multi-regional clinical trial (NCT06712654) of AP306, a first-in-class oral pan-phosphate transporter inhibitor for patients with hyperphosphatemia receiving maintenance hemodialysis, in the form of a trial-in-progress poster at the ASN Kidney Week 2026.This global Phase IIb multi-regional clinical trial is jointly sponsored by Alebund Pharmaceuticals and R1 and is currently being conducted at multiple clinical centers in the United States and China. The company announced on July 21, 2026 that the first subject had been randomized and dosed in this trial. Patient enrollment at clinical centers in the United States and China is currently ongoing. The trial is expected to be completed in the second quarter of 2027, and topline data will be disclosed in due course.For more heavyweight Hong Kong stock news, download the Zhitong Finance app. For more Hong Kong stock and overseas wealth management information, please visit www.zhitongcaijing.com (search for \"Zhitong Finance\"); to join the Zhitong Hong Kong stock investment group, please add the Zhitong customer service WeChat (ztcjkf).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126857983","isCrawlerRequest":true}